You are here
TRIA BIOSCIENCE CORP.
UEI: DGF9K7VZNLU7
# of Employees: 7
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Synthetic Universal Flu Vaccine
Amount: $224,966.00Abstract Type A and B Influenza viruses cause severe seasonal epidemics and less frequent but more deadly pandemic infectionsVaccination provides the best protectionalthough serious problems are confr ...
SBIRPhase I2018Department of Health and Human Services Centers for Disease Control and Prevention -
Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients
Amount: $579,383.00DESCRIPTION (provided by applicant): Allergy is a major cause of illness and disability with an estimated 40-50 million people afflicted in the US alone. AIT provides long-term benefits for the patien ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Cross-Protective Monoclonal Antibodies for treatment of pandemic Flu
Amount: $600,000.00DESCRIPTION (provided by applicant): Influenza is a highly contagious respiratory disease that causes substantial mortality world-wide. There is great international concern that the Avian Influenza v ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Advanced Design of a Nicotine Vaccine for Smoking Cessation
Amount: $352,841.00DESCRIPTION (provided by applicant): Tobacco smoke is the primary cause of lung cancer, cardiovascular disease and premature death, with nearly 5 million people dying each year. Treatments that preven ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.
Amount: $3,000,000.00DESCRIPTION (provided by applicant): H5N1 is a highly pathogenic avian influenza virus that can cause severe disease and death in humans. H5N1 is spreading rapidly in bird populations world-wide and t ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health -
A novel DC-targeting non-integrating lentivector vaccine for HIV infection
Amount: $600,000.00DESCRIPTION (provided by applicant): Despite two decades of persistent research on prophylactic and therapeutic immunization against HIV, an effective vaccine-based solution to the HIV pandemic has re ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Pandemic H5N1 vaccine containing recombinant H5 and a synthetic TLR4 agonist, GLA
Amount: $756,444.00DESCRIPTION (provided by applicant): H5N1 is a highly pathogenic avian influenza virus that can cause severe disease and death in humans. H5N1 is spreading rapidly in bird populations world-wide and t ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health
